Corxel Pharmaceuticals closed a $287 million Series D1 financing to accelerate global development of CX11, an oral small‑molecule GLP‑1 receptor agonist targeting obesity and type 2 diabetes. The round included investors RTW Investments, SR One, RA Capital, HBM, and others and will fund ongoing Phase II/III programs. Corxel reported Phase II results showing ~9.7% and ~9.4% mean body‑weight reductions at 16 weeks, citing oral, once‑daily dosing and potential manufacturing cost advantages over injectable GLP‑1s. CX11 is in a Phase II trial in the U.S. and a Phase III in China, and Corxel recently acquired global rights to the asset. The financing comes amid intensified competition after FDA approval of Novo Nordisk’s Wegovy pill and signals investor appetite for oral obesity therapeutics. Late‑stage success for CX11 would expand the oral GLP‑1 class and disrupt market dynamics dominated by injectables.